183 related articles for article (PubMed ID: 25303899)
21. The clinical and genetic epidemiology of neuronal ceroid lipofuscinosis in Newfoundland.
Moore SJ; Buckley DJ; MacMillan A; Marshall HD; Steele L; Ray PN; Nawaz Z; Baskin B; Frecker M; Carr SM; Ives E; Parfrey PS
Clin Genet; 2008 Sep; 74(3):213-22. PubMed ID: 18684116
[TBL] [Abstract][Full Text] [Related]
22. Gemfibrozil and fenofibrate, Food and Drug Administration-approved lipid-lowering drugs, up-regulate tripeptidyl-peptidase 1 in brain cells via peroxisome proliferator-activated receptor α: implications for late infantile Batten disease therapy.
Ghosh A; Corbett GT; Gonzalez FJ; Pahan K
J Biol Chem; 2012 Nov; 287(46):38922-35. PubMed ID: 22989886
[TBL] [Abstract][Full Text] [Related]
23. The genetic spectrum of human neuronal ceroid-lipofuscinoses.
Mole SE
Brain Pathol; 2004 Jan; 14(1):70-6. PubMed ID: 14997939
[TBL] [Abstract][Full Text] [Related]
24. Lysosome-related genes are regulated in the orbital fat of patients with graves' ophthalmopathy.
Chen MH; Liao SL; Chen MH; Tsou PL; Shih MJ; Chang TC; Chuang LM
Invest Ophthalmol Vis Sci; 2008 Nov; 49(11):4760-4. PubMed ID: 18552385
[TBL] [Abstract][Full Text] [Related]
25. Neuronal ceroid lipofuscinoses and possible pathogenic mechanism.
Zhong N
Mol Genet Metab; 2000; 71(1-2):195-206. PubMed ID: 11001811
[TBL] [Abstract][Full Text] [Related]
26. CLN2 Disease (Classic Late Infantile Neuronal Ceroid Lipofuscinosis).
Kohlschütter A; Schulz A
Pediatr Endocrinol Rev; 2016 Jun; 13 Suppl 1():682-8. PubMed ID: 27491216
[TBL] [Abstract][Full Text] [Related]
27. Altered gene expression in the eye of a mouse model for batten disease.
Chattopadhyay S; Kingsley E; Serour A; Curran TM; Brooks AI; Pearce DA
Invest Ophthalmol Vis Sci; 2004 Sep; 45(9):2893-905. PubMed ID: 15326100
[TBL] [Abstract][Full Text] [Related]
28. Cellular pathology and pathogenic aspects of neuronal ceroid lipofuscinoses.
Kida E; Golabek AA; Wisniewski KE
Adv Genet; 2001; 45():35-68. PubMed ID: 11332776
[TBL] [Abstract][Full Text] [Related]
29. A mouse model for Finnish variant late infantile neuronal ceroid lipofuscinosis, CLN5, reveals neuropathology associated with early aging.
Kopra O; Vesa J; von Schantz C; Manninen T; Minye H; Fabritius AL; Rapola J; van Diggelen OP; Saarela J; Jalanko A; Peltonen L
Hum Mol Genet; 2004 Dec; 13(23):2893-906. PubMed ID: 15459177
[TBL] [Abstract][Full Text] [Related]
30. The neuronal ceroid-lipofuscinoses.
Bennett MJ; Rakheja D
Dev Disabil Res Rev; 2013; 17(3):254-9. PubMed ID: 23798013
[TBL] [Abstract][Full Text] [Related]
31. Fingolimod and Teriflunomide Attenuate Neurodegeneration in Mouse Models of Neuronal Ceroid Lipofuscinosis.
Groh J; Berve K; Martini R
Mol Ther; 2017 Aug; 25(8):1889-1899. PubMed ID: 28506594
[TBL] [Abstract][Full Text] [Related]
32. Neuronal ceroid lipofuscinosis: a common pathway?
Persaud-Sawin DA; Mousallem T; Wang C; Zucker A; Kominami E; Boustany RM
Pediatr Res; 2007 Feb; 61(2):146-52. PubMed ID: 17237713
[TBL] [Abstract][Full Text] [Related]
33. AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL.
Sondhi D; Peterson DA; Giannaris EL; Sanders CT; Mendez BS; De B; Rostkowski AB; Blanchard B; Bjugstad K; Sladek JR; Redmond DE; Leopold PL; Kaminsky SM; Hackett NR; Crystal RG
Gene Ther; 2005 Nov; 12(22):1618-32. PubMed ID: 16052206
[TBL] [Abstract][Full Text] [Related]
34. Late infantile neuronal ceroid lipofuscinosis: a new mutation in Arabs.
Goldberg-Stern H; Halevi A; Marom D; Straussberg R; Mimouni-Bloch A
Pediatr Neurol; 2009 Oct; 41(4):297-300. PubMed ID: 19748052
[TBL] [Abstract][Full Text] [Related]
35. Late-infantile neuronal ceroid lipofuscinosis (CLN2/Jansky-Bielschowsky type) in Oman.
Koul R; Al-Futaisi A; Ganesh A; Rangnath Bushnarmuth S
J Child Neurol; 2007 May; 22(5):555-9. PubMed ID: 17690061
[TBL] [Abstract][Full Text] [Related]
36. Loss of
Savchenko E; Singh Y; Konttinen H; Lejavova K; Mediavilla Santos L; Grubman A; Kärkkäinen V; Keksa-Goldsteine V; Naumenko N; Tavi P; White AR; Malm T; Koistinaho J; Kanninen KM
Dis Model Mech; 2017 Sep; 10(9):1089-1100. PubMed ID: 28733362
[TBL] [Abstract][Full Text] [Related]
37. Homogeneous PCR nucleobase quenching assays to detect four mutations that cause neuronal ceroid lipofuscinosis: T75P and R151X in CLN1, and IVS5-1G>C and R208X in CLN2.
Leman AR; Polochock S; Mole SE; Pearce DA; Rothberg PG
J Neurosci Methods; 2006 Oct; 157(1):124-31. PubMed ID: 16720047
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological Effects on Ceroid Lipofuscin and Neuronal Structure in Cln3
Brenneman DE; Pearce DA; Kovacs A; DeFrees S
J Mol Neurosci; 2017 Sep; 63(1):100-114. PubMed ID: 28812237
[TBL] [Abstract][Full Text] [Related]
39. Quantitative t2 measurements in juvenile and late infantile neuronal ceroid lipofuscinosis.
Paniagua Bravo A; Forkert ND; Schulz A; Löbel U; Fiehler J; Ding X; Sedlacik J; Rosenkranz M; Goebell E
Clin Neuroradiol; 2013 Sep; 23(3):189-96. PubMed ID: 23263384
[TBL] [Abstract][Full Text] [Related]
40. The role of nonsense-mediated decay in neuronal ceroid lipofuscinosis.
Miller JN; Chan CH; Pearce DA
Hum Mol Genet; 2013 Jul; 22(13):2723-34. PubMed ID: 23539563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
